A Review of Proteomics Strategies to Study T-Cell Activation and Function in Cancer Disease.
Antigens, Neoplasm
/ immunology
Chromatography, Liquid
Humans
Immunotherapy
/ methods
Immunotherapy, Adoptive
/ methods
Lymphocyte Activation
/ immunology
Mass Spectrometry
/ methods
Neoplasms
/ immunology
Proteomics
/ methods
Receptors, Chimeric Antigen
/ antagonists & inhibitors
Signal Transduction
/ immunology
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes, Cytotoxic
/ immunology
Tumor Microenvironment
CAR-T
Cytotoxic T-cells
Immunotherapy
LC/MS
Mass Cytometry
Proteomics
T-cell exhaustion
Tumor microenvironment (TME)
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
30
5
2021
pubmed:
31
5
2021
medline:
17
8
2021
Statut:
ppublish
Résumé
Cytotoxic T-cells play a key role in natural response to cancer and in immunotherapy. Understanding in an ever more thorough and complete way the mechanisms underlying their activation and/or those that prevent it is a crucial challenge for the success of the therapy. Proteomics can make a decisive contribution to achieving this goal as it brings together a range of technologies that potentially allow the expression levels of thousands of proteins to be analyzed at the same time. In the first part of this chapter, after an overview of the main mechanisms that determine T-cell dysfunction, new MS-based approaches to characterizing T-cell subpopulations in the tumor microenvironment will be described. The second part of the chapter will focus on the main strategies for cancer immunotherapy, from the selective blockage of inhibitory receptor to CAR T therapy. Examples of proteomics application to tumor microenvironment analysis will be reported to illustrate how these innovative approaches can contribute significantly to understanding the cellular and molecular mechanisms that regulate an effective response to therapy.
Identifiants
pubmed: 34053055
doi: 10.1007/978-1-0716-1507-2_9
doi:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-136Références
Bellone M, Calcinotto A (2013) Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 3:1–15
doi: 10.3389/fonc.2013.00231
Chung A, Lee J, Ferrera N (2010) Targeting the tumour vasculature: insights from physio- logical angiogenesis. Nat Rev Cancer 10:505–514
pubmed: 20574450
doi: 10.1038/nrc2868
Oelkrug C, Ramage JM (2014) Enhancement of T cell recruitment and infiltration into tu- mours. Clin Exp Immunol 178:1–8
pubmed: 24828133
pmcid: 4360188
doi: 10.1111/cei.12382
Maimela NR, Liu S, Zhang Y (2018) Fates of CD8+ T cells in Tumor Microenvironment. Comput Struct Biotechnol J 17:1–13. https://doi.org/10.1016/j.csbj.2018.11.004 . eCollection Review
doi: 10.1016/j.csbj.2018.11.004
pubmed: 30581539
pmcid: 6297055
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904–5912
pubmed: 18836471
pmcid: 3689267
doi: 10.1038/onc.2008.271
Mbeunkui L, Johann DJ (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63:571–582
pubmed: 19083000
doi: 10.1007/s00280-008-0881-9
Becker C, Hald M (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148
pubmed: 23666510
doi: 10.1007/s00262-013-1434-6
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322
doi: 10.1016/j.ccr.2012.02.022
Bucks CM, Norton JA, Boesteanu AC et al (2009) Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol 182:6697–6708
pubmed: 19454664
pmcid: 2923544
doi: 10.4049/jimmunol.0800997
Blackburn SD, Shin H, Haining WN et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29–37
pubmed: 19043418
doi: 10.1038/ni.1679
Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35:51–60
pubmed: 24210163
doi: 10.1016/j.it.2013.10.001
Woo SR, Turnis ME, Goldberg MV et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T- cell function to promote tumoral immune escape. Cancer Res 72:917–927
pubmed: 22186141
doi: 10.1158/0008-5472.CAN-11-1620
Xia A, Zhang Y, Xu J et al (2019) T cell dysfunction in cancer immunity and immunotherapy. Front Immunol 10:1719. https://doi.org/10.3389/fimmu.2019.01719 . eCollection 2019. Review
doi: 10.3389/fimmu.2019.01719
pubmed: 31379886
pmcid: 6659036
Johnston RJ, Comps-Agrar L, Hackney J et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923–937
pubmed: 25465800
doi: 10.1016/j.ccell.2014.10.018
Anderson KG, Stromnes IM, Greenberg PD (2017) Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31:311–325
pubmed: 28292435
pmcid: 5423788
doi: 10.1016/j.ccell.2017.02.008
Merelli B, Massi D, Cattaneo L et al (2014) Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 89:140–165
pubmed: 24029602
doi: 10.1016/j.critrevonc.2013.08.002
Li J, Wang L, Chen X et al (2017) CD39/ CD73 up-regulation on myeloid-derived suppressor cells via TGF- β -mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology e1320011:6
Shi L, Yang L, Wu Z et al (2018) Adenosine signaling: next checkpoint for gastric cancer immunotherapy? Int Immunopharmacol 63:58–65
pubmed: 30075429
doi: 10.1016/j.intimp.2018.07.023
Gholami MD, Kardar GA, Saeedi Y et al (2017) Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanism. Cell Immunol 322:1–14
doi: 10.1016/j.cellimm.2017.10.002
Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–308
pubmed: 16557261
doi: 10.1038/nri1806
Ghiringhelli F, Ménard C, Terme M et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075–1085
pubmed: 16230475
pmcid: 2213209
doi: 10.1084/jem.20051511
Zhou L, Yang K, Wickett RR et al (2016) Dermal fibroblasts induce cell cycle arrest and block epithelial–mesenchymal transition to inhibit the early stage melanoma de- velopment. Cancer Med 5:1566–1579
pubmed: 27061029
pmcid: 4944884
doi: 10.1002/cam4.707
Wang F, Yang L, Gao Q et al (2015) CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother 64:965–976
pubmed: 25944005
doi: 10.1007/s00262-015-1701-9
Yang L, Zhang Y (2017) Tumor-associated macrophages, potential targets for cancer treat- ment. Biomark Res 5:1–6
doi: 10.1186/s40364-017-0106-7
Hanson EM, Clements VK, Sinha P et al (2009) Myeloid- derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8 + t cells. J Immunol 183:937–944
pubmed: 19553533
pmcid: 2800824
doi: 10.4049/jimmunol.0804253
Anderson NL, Anderson NG (1998) Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19(11):1853–1861. https://doi.org/10.1002/elps.1150191103
doi: 10.1002/elps.1150191103
pubmed: 9740045
Zhang Z, Wu S, Stenoien DL et al (2014) High-throughput proteomics. Annu Rev Anal Chem (Palo Alto, Calif) 7:427–454
doi: 10.1146/annurev-anchem-071213-020216
Papale M, Conserva F, Pontrelli P, Gesualdo L (2019) Omics in diabetic kidney disease. In: Roelofs J, Vogt L (eds) Diabetic nephropathy. Springer, Cham. https://doi.org/10.1007/978-3-319-93521-8_28
doi: 10.1007/978-3-319-93521-8_28
Magdeldin S (ed) Recent advances in proteomics research. IntechOpen, London
Bandura DR, Baranov VI, Ornatsky OI et al (2009) Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 81:6813–6822
pubmed: 19601617
doi: 10.1021/ac901049w
Spitzer MH, Nolan GP (2016) Mass cytometry: single cells, many features. Cell 165(4):780–791
pubmed: 27153492
pmcid: 4860251
doi: 10.1016/j.cell.2016.04.019
Winkler F, Bertram Bengsch B (2020) Use of mass cytometry to profile human T cell exhaustion. Front Immunol. https://doi.org/10.3389/fimmu.2019.03039
Bengsch B, Ohtani T, Khan O et al (2018) Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity 48(5):1029–1045.e5
pubmed: 29768164
pmcid: 6010198
doi: 10.1016/j.immuni.2018.04.026
Chew V, Lai L, Pan L et al (2017) Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 114(29):E5900–E5909
pubmed: 28674001
pmcid: 5530700
doi: 10.1073/pnas.1706559114
Kourelis TV, Villasboas JC, Jessen E et al (2019) Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer J 9(9):72
pubmed: 31462637
pmcid: 6713712
doi: 10.1038/s41408-019-0234-4
Day CL, Kaufmann DE, Kiepiela P et al (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350–354
pubmed: 16921384
doi: 10.1038/nature05115
Pauken KE, Sammons MA, Odorizzi PM et al (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160–1165
pubmed: 27789795
pmcid: 5484795
doi: 10.1126/science.aaf2807
Philip M, Fairchild L, Sun L et al (2017) Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545:452–456
pubmed: 28514453
pmcid: 5693219
doi: 10.1038/nature22367
Sadelain M, Rivière I, Riddell S (2017) Therapeutic T cell engineering. Nature 545:423–431
pubmed: 28541315
pmcid: 5632949
doi: 10.1038/nature22395
Cao J, Wang G, Cheng H et al (2018) Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 93:851–858
pubmed: 29633386
doi: 10.1002/ajh.25108
Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295–2306
pubmed: 28924019
pmcid: 5701525
doi: 10.1182/blood-2017-06-793141
Gust J, Hay KA, Hanafi LA et al (2017) Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404–1419
pubmed: 29025771
pmcid: 29025771
doi: 10.1158/2159-8290.CD-17-0698
Fraietta JA, Lacey SF, Orlando EJ et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563–571
pubmed: 29713085
pmcid: 6117613
doi: 10.1038/s41591-018-0010-1
Zolov SN, Rietberg SP, Bonifant CL (2018) Programmed cell death protein 1 activation preferentially inhibits CD28 CAR-T cells. Cytotherapy 20:1259–1266
pubmed: 30309710
doi: 10.1016/j.jcyt.2018.07.005
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262–1278
pubmed: 24906146
pmcid: 4343198
doi: 10.1016/j.cell.2014.05.010
Hu B, Zou Y, Zhang L et al (2018) Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther 30:446–458
pubmed: 29706119
doi: 10.1089/hum.2017.234
Zhang Y, Zhang X, Cheng C et al (2017) CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med 11:554–562
pubmed: 28625015
doi: 10.1007/s11684-017-0543-6
pmcid: 28625015
Li S, Siriwon N, Zhang X et al (2017) Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res 23:6982–6992
pubmed: 28912137
doi: 10.1158/1078-0432.CCR-17-0867
pmcid: 28912137
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
pubmed: 22658127
pmcid: 3544539
doi: 10.1056/NEJMoa1200690
Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894
pubmed: 25667295
pmcid: 25667295
doi: 10.1200/JCO.2014.56.2736
Harel M, Ortenberg R, Varanasi SK et al (2019) Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 179(1):236–250.e18
pubmed: 31495571
pmcid: 7993352
doi: 10.1016/j.cell.2019.08.012
Sade-Feldman M, Jiao YJ, Chen JH et al (2017) Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 8:1136
pubmed: 29070816
pmcid: 5656607
doi: 10.1038/s41467-017-01062-w
Jongsma MLM, Guarda G, Spaapen RM (2017) The regulatory network behind MHC class I expression. Mol Immunol 17:30598–30599
Zhou F (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28:239–260
pubmed: 19811323
doi: 10.1080/08830180902978120
Salter AI, Ivey RG, Kennedy JJ, et al (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11(544). pii: eaat6753
Karlsson H, Svensson E, Gigg C et al (2015) Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS One e0144787:10